Merck

Actelion board nominates two

Wednesday, April 6, 2011 12:40 PM

Actelion has nominated two pharmaceutical executives, including ex-GlaxoSmithKline boss Jean-Pierre Garnier, to join the board after shareholder Elliott Advisors repeated calls for changes in management and strategy, according to Pharma Times.

More... »

Merck to buy Inspire

Tuesday, April 5, 2011 02:59 PM

Merck and Inspire Pharmaceuticals have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products, according to Fierce Biotech.

More... »

Merck pulls out of Portola collaboration

Tuesday, March 29, 2011 12:49 PM

Merck has returned global rights for the investigational clotbuster betrixaban to California-based Portola Pharmaceuticals, according to PharmaTimes.

More... »

Neuroscience drug development slows, requires funding

Tuesday, March 29, 2011 11:49 AM

Many European pharmaceutical companies have significantly reduced their workflow in the realm of neuroscience, according to Fierce Biotech. Companies are challenged with a high risk of trial failure while investors demand new products. 

More... »

PharmaDiagnostics names director

Friday, March 11, 2011 11:39 AM

PharmaDiagnostics has appointed Dr. Sylviane Boucharens director of assay development. She joins from Merck’s MSD site in Newhouse, Scotland, where she was head of global compound repository and in vitro screening.

More... »

Merck fails to win FDA support

Tuesday, March 8, 2011 10:43 AM

Merck, based in Darmstadt, Germany, failed to win FDA support for its multiple sclerosis pill cladribine.

More... »

Merck rejects Organon deal

Monday, March 7, 2011 01:58 PM

Merck told a Dutch court it had to turn down an offer for Organon because it would have cost the company $700 million more than shuttering the operation, according to FierceBiotech.

More... »

Lycera partners with Merck

Thursday, March 3, 2011 03:17 PM

Plymouth, Mich.-based Lycera will receive $12 million upfront and up to $295 million in milestone payments from Merck in a collaboration to discover new anti-inflammatory drugs, according to FierceBiotech. The deal is focused on new small molecules that target T-helper 17 (Th17) cells, key mediators of inflammation and a new approach to treating major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis.

More... »

Fujifilm moves into biologics with Merck buy

Tuesday, March 1, 2011 01:15 PM

Japan's Fujifilm is expanding its drug business in a deal to buy two of Merck's contract manufacturing facilities, according to Fierce Pharma.

More... »

Merck partners with Alectos to develop new type of Alzheimer’s treatment

Monday, August 23, 2010 08:00 AM

Merck has launched a research partnership with Alectos Therapeutics, a Vancouver-based biopharmaceutical company, to develop drugs to fight Alzheimer’s Disease based on an enzyme believed to be involved in the development of the disease and potentially other disorders.

More... »